Monti Jaime M, Jantos Héctor
Department of Pharmacology and Therapeutics, School of Medicine Clinics Hospital, University of the Republic, Montevideo 11600, Uruguay.
Department of Pharmacology and Therapeutics, School of Medicine Clinics Hospital, University of the Republic, Montevideo 11600, Uruguay.
Behav Brain Res. 2018 Feb 26;339:11-18. doi: 10.1016/j.bbr.2017.11.006. Epub 2017 Nov 11.
The effects of the dopamine (DA) D1 and D2 receptor agonists SKF38393, bromocriptine and quinpirole, respectively, on spontaneous sleep were analyzed in adult rats prepared for chronic sleep recordings. Local administration of the DAergic agonists into the dorsal raphe nucleus (DRN) during the light phase of the light-dark cycle induced a significant reduction of rapid-eye movement sleep (REMS) and the number of REM periods. Additionally, bromocriptine and quinpirole significantly increased wakefulness (W). Opposite, the microinjection into the DRN of the DA D1 and D2 receptor antagonists SCH23390 and sulpiride, respectively, significantly augmented REMS and the number of REM periods. Pretreatment with SCH23390 and sulpiride prevented the effects of SKF38393 and bromocriptine, respectively, on sleep variables. Our results tend to indicate that DAergic neurons located in the ventral tegmental area (VTA) and substantia nigra pars compacta (SNc) contribute to the regulation of predominantly W and REMS by DRN serotonergic neurons.
分别分析多巴胺(DA)D1和D2受体激动剂SKF38393、溴隐亭和喹吡罗对成年大鼠自发睡眠的影响,这些大鼠已准备好进行慢性睡眠记录。在明暗周期的光照阶段,将DA能激动剂局部注射到中缝背核(DRN)中,可显著减少快速眼动睡眠(REMS)和快速眼动期的数量。此外,溴隐亭和喹吡罗可显著增加清醒时间(W)。相反,分别向DRN中微量注射DA D1和D2受体拮抗剂SCH23390和舒必利,可显著增加REMS和快速眼动期的数量。用SCH23390和舒必利预处理分别可防止SKF38393和溴隐亭对睡眠变量的影响。我们的结果倾向于表明,位于腹侧被盖区(VTA)和黑质致密部(SNc)的DA能神经元通过DRN 5-羟色胺能神经元对主要的清醒和REMS调节起作用。